Bixiye
Cablivi (caplacixumab-yhdp) - Commercial
Prior Authorization, Quantity Limit
Taariikhda wax ku ool ah ee barnaamijka: Jun 01, 2025
Natiijooyinka Raadinta
Soo bandhiga 2441 - 2450 ee natiijooyinka 4128
Bixiye
QP45-21 Medical Drug Update for Botulinum Toxins (Myobloc, Botox, Dysport, Xeomin) - Commercial Products
Taariikhda uu dhaqangalayo Barnaamijka: May 26, 2021
Bixiye
QP46-21 Incorrect ID Cards Issued for Minnesota Health Care Programs Members
Taariikhda uu dhaqangalayo Barnaamijka: May 26, 2021
Bixiye
QP43-21 MHCP Pharmacy Benefit Exclusion for Jemperli and Zynlonta™
Taariikhda uu dhaqangalayo Barnaamijka: May 26, 2021
Bixiye
QP44-21 MHCP Pharmacy Benefit Update – New Drug-Related Prior Authorization (PA) with Quantity Limit (QL) Criteria: Zeposia® (ozanimod)
Taariikhda uu dhaqangalayo Barnaamijka: May 26, 2021
Bixiye
2021 June Provider Press
Taariikhda uu dhaqangalayo Barnaamijka: May 25, 2021
Bixiye
QP41-21 Commercial and MHCP Pharmacy Benefit Exclusion for Qutenza®
Taariikhda uu dhaqangalayo Barnaamijka: May 12, 2021
Bixiye
QP40-21 Commercial Pharmacy Benefit Update – New and Revised Drug-Related Prior Authorization (PA) Requirement Notification – Effective July 1, 2021
Taariikhda uu dhaqangalayo Barnaamijka: May 12, 2021